| 2009 |
Christine Kriete |
Peculiarities and Challenges of Herbal Medicinal Products - Assessment of Herbal Medicinal Products within the Regulatory Environments of the European Community and the United States *** |
|
|
| 2009 |
Dr. Susanne Lange |
The new Variation Regulation. A major step forward? *** |
|
|
| 2009 |
Dr. Susanne Manhart |
Development of a New Active Substance for Treatment of Alzheimers Disease Development from Preclinical Testing to Proof-of-Concept *** |
|
|
| 2009 |
Dr. Uta Maucher |
Product Quality Review: New requirements related to medicinal products |
|
|
| 2009 |
Dr. Nicole Max |
Legal proposal to allow pharmaceutical companies to provide information to patients on prescription-only medicines a controversial discussion *** |
|
|
| 2009 |
Dr. Annette Mayer |
Evaluation and safety assessment of botanical preparations intended for the use in food supplements *** |
|
|
| 2009 |
Dr. Stephanie Mondabon |
The European Commissions "Pharmaceutical Package": An Analysis *** |
|
|
| 2009 |
Dr. Christel Neiteler |
Classification Issues on the Borderline between Medical Devices and Medicinal Products - Review of the Current Regulatory Discussions and Decisions *** |
|
|
| 2009 |
Anna Paulina Paul |
The Polish Pharmaceutical Law Strenghts and Weaknesses 5 Years after Accession to the European Union. Analysis. *** |
|
|
| 2009 |
Dr. Christa Pfleiderer |
Regulatory Requirements for Pharmaceuticals, Biotechnological Products, and Biosimilars in Latin America: Common Requirements and Differences |
|
|
| 2009 |
Dr. Maria Teresa Piccini |
FDA programs to expedite innovative drug development and review process: Fast Track, Priority Review and Accelerated Approval *** |
|
|
| 2009 |
Dr. Agnieszka Pietas |
Non-Clinical and Clinical Development of Advanced Therapy Medicinal Products (ATMPs) |
|
|
| 2009 |
Dr. Ulrich Reichert |
Implementing the Guideline on the Specification Limits for Residues of Metal Catalysts or Metal Reagents (EMEA/CHMP/SWP/4446/2000) *** |
|
|
| 2009 |
Ralf Rickert |
A Review of the Availability of Information on Ethics Committee Requirements for Clinical Trials in the EU *** |
|
|
| 2009 |
Dr. Marcus Riehl |
New provisions for the Regulation on Maximum Residue Limits *** |
|
|
| 2009 |
Angela Röder |
Impact of the genotoxic requirements on the generic industry |
|
|
| 2009 |
Dr. Birgitta Sauer |
Nonclinical and Clinical Requirements for the Development of an Anticancer Drug Intended for Treatment of Advanced or Late-Stage Disease - The European Perspective *** |
|
|
| 2009 |
Dr. Werner Schmidt |
Legal Status of Donor-Lymphocyte Infusions manufactured by transiently activated Memory T cells in the context of the European Regulatory Framework |
|
|
| 2009 |
Dr. Olaf Stamm |
Pathogen safety concepts for Biopharmaceuticals |
|
|
| 2009 |
Josephine Stiebler |
Maintaining compliance with GRP while changing the business process aiming to be able to submit new applications in electronic format (eCTD, paperless) appropriately by end of 2009 |
|
|